Weight loss fixes fatty liver—but drugs and diet work differently
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Two ways to lose weight—eating less or taking a drug—both shrink fat in the liver equally. But the drug also helps blood sugar and fat production in the liver while you're taking it. When you stop the drug, those benefits vanish and your body sends out strange signals that might make you gain...
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 560 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Two ways to lose weight—eating less or taking a drug—both shrink fat in the liver equally. But the drug also helps blood sugar and fat production in the liver while you're taking it. When you stop the drug, those benefits vanish and your body sends out strange signals that might make you gain...
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 560 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Authors
Moolla A, Poolman T, Othonos N, Dong J, Smith K, Cornfield T, White S, Ray DW, Mouchti S, Mózes FE, Thomaides-Brears H, Neubauer S, Cobbold JF, Hodson L, Tomlinson JW
Related Content
Claims (6)
GLP-1 receptor agonists confer cardiovascular and metabolic benefits in type 2 diabetes and prediabetes through direct receptor-mediated mechanisms that are independent of weight loss and distinct from endogenous incretin enhancement.
In people with MASLD but without diabetes, losing the same amount of weight through diet and exercise or through liraglutide medication leads to similar decreases in liver fat and liver enzyme levels, suggesting that weight loss is the main factor improving liver health.
In adults with fatty liver disease who do not have diabetes, taking liraglutide for 12 weeks leads to better blood sugar control and lower liver fat production compared to weight loss from lifestyle changes, but these improvements disappear once the medication is stopped.
In adults with MASLD who do not have type 2 diabetes, stopping liraglutide leads to measurable increases in specific blood proteins and changes in gene activity in fat tissue after 12 weeks, but similar changes are not seen when people stop lifestyle changes like diet and exercise.
In people with MASLD but without diabetes, liraglutide improves blood sugar and fat levels without altering gene activity in fat tissue, proteins in the blood, or gut bacteria during treatment.